Defining progression in nonmuscle invasive bladder cancer: It is time for a new, standard definition

Journal of Urology

Volumn 191, Issue 1, 2014, Pages 20-27

  Lamm, Donald ^a   Persad, Raj ^b   Brausi, Maurizio ^c   Buckley, Roger ^d   Witjes, J Alfred ^e   Palou, Joan ^f   Böhle, Andreas ^g   Kamat, Ashish M ^h   Colombel, Marc ⁱ   Soloway, Mark ^j  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b BRISTOL UROLOGICAL INSTITUTE   (United Kingdom)

^c AUSL Modena   (Italy)

^d NORTH YORK GENERAL HOSPITAL   (Canada)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HELIOS AGNES KARLL HOSPITAL   (Germany)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITÉ LYON 1   (France)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

administration; BCG vaccine; disease progression; drug therapy; intravesical; urinary bladder neoplasms

Indexed keywords

BCG VACCINE; EPIRUBICIN; MITOMYCIN;

BLADDER METASTASIS; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; HUMAN; LAMINA PROPRIA; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NATIONAL HEALTH ORGANIZATION; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR INVASION; ADVANCED CANCER; ADVERSE OUTCOME; CANCER SIZE; DISEASE COURSE; DISTANT METASTASIS; LYMPH NODE METASTASIS; STANDARD; SYSTEMATIC REVIEW;

ADMINISTRATION; BACILLUS CALMETTE-GUÉRIN; BCG; BCG VACCINE; CARCINOMA IN SITU; CIS; DISEASE PROGRESSION; DRUG THERAPY; INTRAVESICAL; MITOMYCIN C; MMC; NMIBC; NONMUSCLE INVASIVE BLADDER CANCER; TRANSURETHRAL RESECTION OF THE BLADDER TUMOR; TURBT; URINARY BLADDER NEOPLASMS;

DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84890120075     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.07.102     Document Type: Review

References (48)

1. H.W. Herr, C.M. Pinsky, and W.F. Whitmore Jr. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder J Urol 135 1986 265
2. J.A. Martínez-Piñeiro, J. Jiménez León, and L. Martínez-Piñeiro Jr. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer J Urol 143 1990 502
3. H.W. Herr, D.M. Schwalb, and Z.F. Zhang Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404
4. A. Pawinski, R. Sylvester, and K.H. Kurth A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer J Urol 156 1996 1934
5. M.S. Cookson, H.W. Herr, and Z.F. Zhang The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62
6. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124
7. R.J. Sylvester, van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
8. A. Böhle, and P.R. Bock Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 2004 682
9. P.U. Malmström, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247
10. R.T. Divrik, A.F. Sahin, and U. Yildirim Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial Eur Urol 58 2010 185
11. G. Di Lorenzo, S. Perdonà, and R. Damiano Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial Cancer 116 2010 1893
12. R.J. Sylvester, M.A. Brausi, and W.J. Kirkels Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage TaT1 urothelial carcinoma of the bladder Eur Urol 57 2010 766
13. J. Oddens, M. Brausi, and R. Sylvester Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462
14. M.D. Shelley, G. Jones, and A. Cleves Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review BJU Int 109 2012 496
15. A. Stenzl, H. Penkoff, and E. Dajc-Sommerer Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial Cancer 117 2011 938
16. Merriam-Webster Online. Available at www.merriam-webster.com/dictionary/ progression. Accessed October 10, 2012.
17. MedlinePlus Medical Dictionary. Available at www.merriam-webster.com/ medlineplus/progressive. Accessed October 10, 2012.
18. Taber's Online: Taber's Medical Dictionary. Available at www.tabers.com/tabersonline/ub/view/Tabers/143846/47/progression?q=Progression. Accessed October 10, 2012.
19. National Cancer Institute at the National Institutes of Health: NCI Dictionary of Cancer Terms. Available at www.cancer.gov/dictionary?cdrid=44078. Accessed October 10, 2012.
20. S.M. Di Stasi, A. Giannantoni, and A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43
21. R.R. de Vries, J.A. Nieuwenhuijzen, and A. Vincent Survival after cystectomy for invasive bladder cancer Eur J Surg Oncol 36 2010 292
22. S.F. Altekruse, C.L. Kosary, and M. Krapcho SEER Cancer Statistics Review, 1975-2007 (based on November 2009 SEER data submission) 2010 National Cancer Institute Bethesda, Maryland Available at http://seer.cancer.gov/csr/ 1975-2007/
23. G.R. Prout Jr., B.A. Barton, and P.P. Griffin Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group J Urol 148 1992 1413
24. B. Leblanc, A.J. Duclos, and F. Bénard Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder J Urol 162 1999 1946
25. H.W. Herr Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome J Urol 163 2000 60
26. T. Lebret, D. Bohin, and Z. Kassardjian Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations J Urol 163 2000 63
27. A. van der Meijden, R. Sylvester, and L. Collette The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials J Urol 164 2000 1533
28. R.J. Sylvester, A.P. van der Meijden, and J.A. Witjes High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder Urology 66 2005 90
29. Amin MB, Reuter VE, Epstein JI, et al. Pathology consensus guidelines by the pathology of bladder cancer work group. In: Bladder Cancer. Edited by M Soloway and S Khoury. Paris: ICUD-EAU 2012; pp 63-168.
30. A.M. Nieder, M. Brausi, and D. Lamm Management of stage T1 tumors of the bladder: International Consensus Panel Urology 66 2005 108
31. E. Pasin, D.Y. Josephson, and A.P. Mitra Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history Rev Urol 10 2008 31
32. D. Cao, R.T. Vollmer, and J. Luly Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma Urology 76 2010 593
33. F. Millán-Rodríguez, G. Chéchile-Toniolo, and J. Salvador-Bayarri Multivariate analysis of the prognostic factors of primary superficial bladder cancer J Urol 163 2000 73
34. M. May, S. Brookman-Amissah, and J. Roigas Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications Eur Urol 57 2010 850
35. D.L. Lamm Carcinoma in situ Urol Clin North Am 19 1992 499
36. G. Jakse, R. Hall, and A. Bono Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 Eur Urol 40 2001 144
37. D.C. Chade, S.F. Shariat, and A. Adamy Clinical outcome of primary versus secondary bladder carcinoma in situ J Urol 184 2010 464
38. Burger M, Witjes F, Babjuk M, et al. High-grade Ta, CIS and T1 urothelial carcinoma. In: Bladder Cancer. Edited by M Soloway and S Khoury. Paris: ICUD-EAU 2012; pp 247-268.
39. M. Babjuk, M. Burger, and R. Zigeuner Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) 2013 European Association of Urology Arnhem, the Netherlands Available at www.uroweb.org/gls/pdf/05-TaT1-Bladder-Cancer-LR.pdf Accessed April 15, 2013
40. M. Burger, M.N. van der Aa, and J.M. van Oers Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study Eur Urol 54 2008 835
41. J. Fernández-Gomez, E. Solsona, and M. Unda Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992
42. A. Orsola, I. Trias, and C.X. Raventós Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients Eur Urol 48 2005 231
43. A. Orsola, L. Cecchini, and C.X. Raventós Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette- Guérin therapy and the decision for a repeat TUR BJU Int 105 2010 202
44. J. Palou, R.J. Sylvester, and O.R. Faba Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118
45. G.N. Thalmann, F. Birkhäuser, and B. Roth Management of pT1G3 bladder cancer Eur Urol Suppl 10 2011 e1
46. L. Cheng, A.L. Weaver, and R.M. Neumann Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal Cancer 86 1999 1035
47. L. Cheng, R.M. Neumann, and A.L. Weaver Predicting cancer progression in patients with stage T1 bladder carcinoma J Clin Oncol 17 1999 3182
48. B.W. van Rhijn, T.H. van der Kwast, and S.S. Alkhateeb A new and highly prognostic system to discern T1 bladder cancer substage Eur Urol 61 2012 378